Search

Your search keyword '"Ljungman, Per"' showing total 25 results
Start Over Author "Ljungman, Per" Journal transplantation
25 results on '"Ljungman, Per"'

6. Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Disorders: Experience in a Single Center

Author

Ringdén, Olle, primary, Remberger, Mats, additional, Svahn, Britt-Marie, additional, Barkholt, Lisbeth, additional, Mattsson, Jonas, additional, Aschan, Johan, additional, Le Blanc, Katarina, additional, Gustafsson, Britt, additional, Hassan, Zuzana, additional, Omazic, Brigitta, additional, Svenberg, Petter, additional, Solders, Göran, additional, von Döbeln, Ulrika, additional, Winiarski, Jacek, additional, Ljungman, Per, additional, and Malm, Gunilla, additional

Published
2006
Full Text
View/download PDF

10. THE ROLE OF HEPATITIS C AND B VIRUS INFECTIONS AS RISK FACTORS FOR SEVERE LIVER COMPLICATIONS FOLLOWING ALLOGENEIC BMT: A PROSPECTIVE STUDY BY THE INFECTIOUS DISEASE WORKING PARTY OF THE EUROPEAN BLOOD AND MARROW TRANSPLANTATION GROUP1

Author

Locasciulli, Anna, primary, Testa, Marina, additional, Valsecchi, Maria G., additional, Bacigalupo, Andrea, additional, Solinas, Stefano, additional, Tomas, Jos?? F., additional, Ljungman, Per, additional, and Alberti, Alfredo, additional

Published
1999
Full Text
View/download PDF

23. LYMPHOCYTE RESPONSES AFTER CYTOMEGALOVIRUS INFECTION IN BONE MARROW TRANSPLANT RECIPIENTS—A ONEYEAR FOLLOWUP

Author

LJUNGMAN, PER, LÖNNQVIST, BERIT, WAHREN, BRITTA, RINGDÉN, OLLE, and GAHRTON, GÖSTA

Abstract

A group of 46 bone marrow transplant (BMT) recipients were studied by lymphocyte stimulation with cytomegalovirus (CMV) antigen before, and repeatedly in the first year after, BMT. Of these, 25 patients developed CMV infection and 68 of these got a positive lymphocyte response to CMV.

Published
1985

24. IgGSUBCLASSSPECIFIC CMV REACTIVITY IN BONE MARROW TRANSPLANT RECIPIENTS

Author

WAHREN, BRITTA, LINDE, ANNIKA, SUNDQVIST, VIVI-ANNE, LJUNGMAN, PER, LÖNNQVIST, BERIT, and RLNGDÉN, OLLE

Abstract

IgG subclasses of cytomegalovirus (CMV) antiviral antibodies were determined in 37 donor-recipient pairs of bone marrow transplants (BMT). Bone marrow transplant recipients, like healthy persons, have a restricted immune reactivity, producing mainly two types of anti-CMV IgG: IgG1 and IgG3. Passively transfused specific antibody subclasses were readily measurable. Take of the transplant could be detected from the production of subclass IgG antiviral antibody 1–3 months after BMT of seronegative recipients with marrow from seropositive donors.

Published
1984

25. DOES HIGHDOSE INTRAVENOUS IMMUNE GLOBULIN TREATMENT AFTER BONE MARROW TRANSPLANTATION INCREASE MORTALITY IN VENOOCCLUSIVE DISEASE OF THE LIVER

Author

KLAESSON, SVEN, RINGDÉN, OLOV, LJUNGMAN, PER, ASCHAN, JOHAN, HÄGGLUND, HANS, and WINIARSKI, JACEK

Abstract

Forty-five recipients of bone marrow from HLA-identical siblings were given intravenous immune globulin (IVIG) 0.5 g/kg once a week during the first 3 months after transplantation. Fifty-three consecutive previously transplanted HLA-identical siblings were included as controls. Only patients who were cytomegalovirus (CMV) seropositive or had a CMV-seropositive donor were included. There were no major differences in patient characteristics between the two groups. However, more patients in the IVIG group received individualized graft-versus-host disease (GVHD) prophylaxis with less cyclosporine (P<0.01), more controls received liposomal amphotericin B (P=0.01), and more patients in the IVIG group received low-dose heparin as prophylaxis against veno-occlusive disease of the liver (P<0.001). Median follow-up was 21 months in the IVIG group and 47 months in the control group. There were no differences between the groups with regard to time to engraftment, hospitalization time, or days with fever. No differences between the IVIG group and control group were detected in the incidence of acute GVHD grade II-IV (17 vs. 23) or chronic GVHD (30 vs. 42). The incidence of bacterial septicemias (53 vs. 63) and invasive fungal infections (9 vs. 6) was unaffected by IVIG treatment. The incidence of symptomatic CMV infection was the same in the two groups (14 vs. 16). One control patient died of CMV interstitial pneumonitis, and 1 patient from each group died from viral interstitial pneumonitis of other origin. The incidence of veno-occlusive disease (VOD) was 16 in the IVIG group versus 6 in the controls (P=NS). Fatal VOD occurred in 11 of the IVIG group compared with none of the controls (P=0.02). Other transplant-related complications did not differ between the two groups. Two-year survival was 62 in the IVIG group and 60 in the controls (P=NS). No significant beneficial effect was seen with IVIG, which may increase mortality in VOD. The use of high dose IVIG as prophylaxis in marrow transplant recipients is questioned.

Published
1995

Catalog

Books, media, physical & digital resources
See catalog results